"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...

Get Pro-Level Earnings Insights Before the Market Moves Novo Nordisk A/S NVO, the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

Novo Nordisk cites 44 adverse events, including 38 serious cases and one death, linked to compounded liraglutide since 2017. Testing revealed impurities and fibril formation in unapproved ...

In December, Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of ...